EMA’s CHMP Recommends the Approval of Two Biosimilar Referencing Lilly’s Forsteo (teriparatide) for the Treatment of Osteoporosis

 EMA’s CHMP Recommends the Approval of Two Biosimilar Referencing Lilly’s Forsteo (teriparatide) for the Treatment of Osteoporosis

EMA’s CHMP Recommends the Approval of Two Biosimilar Referencing Lilly’s Forsteo (teriparatide) for the Treatment of Osteoporosis

Shots:

  • The CHMP has adopted the positive opinion recommending the approval of Theramex’s  Livogiva (biosimilar, teriparatide) intended for the treatment of osteoporosis and will be available as a solution for injection (20 micrograms/80 microliters)
  • The CHMP has also recommend marketing authorization to EuroGenerics’ Qutavina (biosimilar, teriparatide) to treat osteoporosis, also available as a solution for injection (20 micrograms/80 microliters)
  • Both Livogiva and Qutavina are the biosimilar referencing Lilly’s Forsteo (teriparatide) which has received authorization in EU in 2003

Theramex, EuroGenerics to read full press release/ article | Ref: EMA | Image: Theramex & EuroGenerics

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post